Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y0KY
|
|||
| Former ID |
DIB009520
|
|||
| Drug Name |
ISIS-APO(a)
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Coronary artery disease [ICD-11: BA80; ICD-10: I25.1, I25.4] | Phase 2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apolipoprotein A messenger RNA (LPA mRNA) | Target Info | . | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Plasminogen activating cascade | |||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | LDL-mediated lipid transport | |||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02160899) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Patients With High Lipoprotein(a). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.